|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulinoma-associated protein-2 (IA-2) is a major autoantigen in type 1 diabetes that occurs through autoimmune-mediated beta-cell destruction.
|
17192463 |
2007 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Insulinoma-associated protein 2 (IA-2) is a major target of autoimmunity in type 1 diabetes.
|
26564179 |
2016 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulinoma-associated protein 2 (IA-2) is a major target of autoimmunity in type 1 diabetes.
|
26564179 |
2016 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 150 infants with a first-degree family history of type 1 diabetes and a risk HLA genotype were randomly assigned to a first gluten exposure at age 6 months (control group) or 12 months (late-exposure group) and were followed 3 monthly until the age of 3 years and yearly thereafter for safety (for growth and autoantibodies to transglutaminase C [TGCAs]), islet autoantibodies to insulin, GAD, insulinoma-associated protein 2, and type 1 diabetes.
|
21515839 |
2011 |
|
Gestational Diabetes
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A total of 764 mothers with non-autoimmune (GAD65, insulinoma-associated protein 2 [IA-2] and insulin autoantibody-negative) GDM were ascertained between September 2000 and August 2004 in the population-based Diabetes Prediction in Skåne (DiPiS) study.
|
19347328 |
2009 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among these, GAD(114-123), GAD(536-545) and IA-2(805-813) were recognized by 53%, 25%, and 42% of T1D patients, respectively.
|
17513797 |
2007 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
At diagnosis of type 1 diabetes (between ages 0.5 and 16.3 yr, n = 470), autoantibodies [glutamic acid decarboxylase (GAD), insulinoma-associated protein 2 (IA2), insulin autoantibodies (IAA), and/or islet cell antibody (ICA)] were positive (ab+) in 330 and negative in 37 (unknown in 103).
|
21518407 |
2011 |
|
Diabetes
|
0.080 |
Biomarker
|
disease |
BEFREE |
Autoantibody-negative patients were retested at median diabetes duration of 3.2 yr (range 0.9-16.2) for autoantibodies (GAD, IA2, ZnT8), human leukocyte antigen (HLA) typing, non-fasting C-peptide, and sequencing of HNF4A, HNF1A, KCNJ11, and INS.
|
21518407 |
2011 |
|
Diabetes Mellitus
|
0.080 |
Biomarker
|
group |
BEFREE |
Autoantibody-negative patients were retested at median diabetes duration of 3.2 yr (range 0.9-16.2) for autoantibodies (GAD, IA2, ZnT8), human leukocyte antigen (HLA) typing, non-fasting C-peptide, and sequencing of HNF4A, HNF1A, KCNJ11, and INS.
|
21518407 |
2011 |
|
Diabetes
|
0.080 |
Biomarker
|
disease |
BEFREE |
Crystal structure of the major diabetes autoantigen insulinoma-associated protein 2 reveals distinctive immune epitopes.
|
17192463 |
2007 |
|
Diabetes Mellitus
|
0.080 |
Biomarker
|
group |
BEFREE |
Crystal structure of the major diabetes autoantigen insulinoma-associated protein 2 reveals distinctive immune epitopes.
|
17192463 |
2007 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, younger age, earlier age at onset, higher HbA1c levels, higher frequency of Glutamic acid decarboxylase antibodies (GADA) and Insulinoma Associated-2 Autoantibodies (IA-2A) were observed in T1D patient carriers of CT genotype.
|
26051683 |
2015 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Islet-targeting autoantibodies that target insulin, 65 kDa glutamic acid decarboxylase, insulinoma-associated protein 2 and zinc transporter 8 - all of which are proteins associated with secretory granules in β-cells - are biomarkers of T1DM-associated autoimmunity that are found months to years before symptom onset, and can be used to identify and study individuals who are at risk of developing T1DM.
|
28358037 |
2017 |
|
Diabetes
|
0.080 |
Biomarker
|
disease |
BEFREE |
Neither GAD- nor IA2-specific TCRs mediated T-cell islet infiltration or diabetes even though T-cells developed in these Rg mice and responded to their cognate epitope.
|
18299317 |
2008 |
|
Diabetes Mellitus
|
0.080 |
Biomarker
|
group |
BEFREE |
Neither GAD- nor IA2-specific TCRs mediated T-cell islet infiltration or diabetes even though T-cells developed in these Rg mice and responded to their cognate epitope.
|
18299317 |
2008 |
|
Severe hypoglycaemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neither the frequency of severe hypoglycemia nor positivity to GAD65 and insulinoma-associated protein 2 antibodies was associated with increased weight gain with either intensive or conventional therapy.
|
14514648 |
2003 |
|
Diabetes
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Neurogenin3 (Ngn3) and neurogenic differentiation 1 (NeuroD1), two crucial transcriptional factors involved in human diabetes (OMIM: 601724) and islet development, have been previously found to directly target to the E-boxes of the insulinoma-associated 2 (Insm2) gene promoter, thereby activating the expression of Insm2 in insulin-secretion cells.
|
30359270 |
2018 |
|
Diabetes Mellitus
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Neurogenin3 (Ngn3) and neurogenic differentiation 1 (NeuroD1), two crucial transcriptional factors involved in human diabetes (OMIM: 601724) and islet development, have been previously found to directly target to the E-boxes of the insulinoma-associated 2 (Insm2) gene promoter, thereby activating the expression of Insm2 in insulin-secretion cells.
|
30359270 |
2018 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Reverse transcriptase-polymerase chain reaction and dual-color fluorescence in situ hybridization analyses confirmed the existence of the AP12/MLT1 fusion gene in the lymphoma cells.
|
15293572 |
2004 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reverse transcriptase-polymerase chain reaction and dual-color fluorescence in situ hybridization analyses confirmed the existence of the AP12/MLT1 fusion gene in the lymphoma cells.
|
15293572 |
2004 |
|
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reverse transcriptase-polymerase chain reaction and dual-color fluorescence in situ hybridization analyses confirmed the existence of the AP12/MLT1 fusion gene in the lymphoma cells.
|
15293572 |
2004 |
|
Diabetes
|
0.080 |
Biomarker
|
disease |
BEFREE |
Risk factors for rapid development of diabetes in this young population were FDR status and initial positivity for GADA, IA-2, and IAA or a combination of GADA and IAA.
|
24034790 |
2014 |
|
Diabetes Mellitus
|
0.080 |
Biomarker
|
group |
BEFREE |
Risk factors for rapid development of diabetes in this young population were FDR status and initial positivity for GADA, IA-2, and IAA or a combination of GADA and IAA.
|
24034790 |
2014 |
|
Impaired glucose tolerance
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Targeted deletion of Insm2 in mice result in reduced insulin secretion and glucose intolerance.
|
30359270 |
2018 |
|
Diabetes
|
0.080 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+) FDRs) of type 1 diabetic patients.
|
19898832 |
2010 |